Current Monitoring in a Microchannel with Repeated Constrictions for Accurate Detection of Sample Location in Isotachophoresis by Merav Karsenty (1694221)

“…We demonstrate the use of the technique to deliver sample to a designated location in the channel with an accuracy as low as 50 μm. …”

Current Monitoring in a Microchannel with Repeated Constrictions for Accurate Detection of Sample Location in Isotachophoresis by Merav Karsenty (1694221)

“…We demonstrate the use of the technique to deliver sample to a designated location in the channel with an accuracy as low as 50 μm. …”

R-loop accumulation at the origins of gene bodies in SAMHD1-deficient AGS patient fibroblasts. by Kiwon Park (6492266)

Brain regions with significant metabolic inhibition (p < 0.001, K = 50) (A) and activation (B) in rats following cocaine self-administration compared to baseline. Cluster location... by Christopher Rowan (21499924)

Screening for K⁺ channel mutants with altered susceptibility to <i>V. cholerae.</i> by Longjun Pu (20685717)

S5 Fig - by Jérémie Le Pen (18551533)

“…KO, knockout; PLSCR1, phospholipid scramblase 1; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; WB, western blot; WT, wild type.…”

TIP47 is involved in HCV RNA replication <i>via</i> interaction with NS5A. by Dorothee A. Vogt (247917)

“…Values are expressed as fold increase of luciferase (RLU) per well, over a 4 h time point (mean ± standard deviation; n = 3, *P<0.05, **P<0.01, ***P<0.001). The decrease of A₉-I₁₂ and W₉-I₁₂ is significant in relation to WT (indicated in grey *), whereas the increase in A₉-V₁₂ is significant in relation to A₉-I₁₂ where indicated (indicated in black *). …”

I-O functions in CA1 neurons in slices from TG and WT mice 9 months post-irradiation. by Emil Rudobeck (4630822)

“…Inset: Original trace and measurement of pV amplitude is indicated with arrows. (B) Irradiation of WT mice (0.5 Gy) increased the slopes of the fEPSP by ~36% when compared to WT controls. …”

Baseline characteristics. by Daniela Sánchez-Santiesteban (21192342)

“…The RII indicated a 50% higher risk of death in the lowest income group (RII: 1.50; 95% CI: 1.13–1.99), while the SII revealed an absolute difference of 0.16 deaths per 1,000 individuals (p=0.01).…”

Composite age-depth model and sediment accumulation rate for BF19 & BF87. by John A. F. Wendt (19976392)

Fig 4 - by Hyuk Sung Yoon (20208672)

Fig 4 - by Leena Inkilä (20614460)

Cisd2KO mice exhibit cardiac electromechanical dysfunctions that are similar to those observed in the naturally aged WT mice. by Chi-Hsiao Yeh (7474556)

“…Mouse number <i>n</i> ≥ 5 for each group. Values for each data point can be found in <a href="http://www.plosbiology.org/article/info:doi/10.1371/journal.pbio.3000508#pbio.3000508.s001" target="_blank">S1 Data</a>. 3M, 3 months old; 6M, 6 months old; 26M, 26 months old; APC, atrial premature complex; AV, atrioventricular; Cisd2KO, CDGSH iron-sulfur domain-containing protein 2 KO; ECG, electrocardiography; KO, knockout; MRI, magnetic resonance imaging; QTc, corrected QT; VPC, ventricular premature complex; WT, wild type.…”

Mean scores of IB-DE, IH-DE, and IB-DE items in Sample 1 and Sample 2 as well as women and men across the samples. by Aistė Ambrasė (22505574)

Poly(ionic liquid) Electrolytes for a Switchable Silver Mirror by Xiao Hou (3228048)

“…These findings were used to guide fabrication of a 50 cm² mirror dynamic window and flexible display. …”

Effects of different concentrations of propofol on the survival rate of zebrafish embryos and larvae. by Yali Ge (417371)

DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”